Recombinant coagulation factor VIIa – from molecular to clinical aspects of a versatile haemostatic agent

Abstract Recombinant factor VIIa (rFVIIa, NovoSeven® ) is currently the only bypassing agent produced by recombinant technology for the treatment of haemophiliacs whose disease is complicated by inhibitory antibodies. In addition, recombinant production of FVIIa has made it widely available for a va...

Full description

Saved in:
Bibliographic Details
Published in:Thrombosis research 2010-06, Vol.125 (6), p.483-489
Main Authors: Persson, Egon, Bolt, Gert, Steenstrup, Thomas D, Ezban, Mirella
Format: Article
Language:English
Subjects:
Biological and medical sciences
Blood and lymphatic vessels
Blood. Blood coagulation. Reticuloendothelial system
Cardiology. Vascular system
Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
Drug Industry - methods
Factor VIIa - adverse effects
Factor VIIa - chemistry
Factor VIIa - pharmacokinetics
Factor VIIa - therapeutic use
Hematology, Oncology and Palliative Medicine
Hemophilia A - complications
Hemophilia A - drug therapy
Hemophilia A - immunology
Hemostatics - adverse effects
Hemostatics - pharmacokinetics
Hemostatics - therapeutic use
Humans
Medical sciences
Pharmacology. Drug treatments
Recombinant Proteins - adverse effects
Recombinant Proteins - chemistry
Recombinant Proteins - pharmacokinetics
Recombinant Proteins - therapeutic use
Structure-Activity Relationship
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Recombinant factor VIIa (rFVIIa, NovoSeven® ) is currently the only bypassing agent produced by recombinant technology for the treatment of haemophiliacs whose disease is complicated by inhibitory antibodies. In addition, recombinant production of FVIIa has made it widely available for a variety of purposes and accelerated the growth of our knowledge about FVIIa by generating an abundance of clinical and biochemical data. This fascinating molecule has turned out to be a safe haemostatic agent with great potential in the clinic and has inspired the generation of improved variants currently in (pre-)clinical testing. The present review describes the structural and functional aspects of FVIIa, followed by sections dealing with the manufacturing, therapeutic mechanism of action, clinical development and experience with rFVIIa.
ISSN:0049-3848
1879-2472
DOI:10.1016/j.thromres.2009.11.027